DNDi aims to deliver from its HCV-specific portfolio:

 

  • Affordable combinations of Direct Acting Antiretrovirals (DAAs) that will be optimal for public health use.

Development

Development

Ravidasvir / Sofosbuvir

 

For more details on each project, see DNDi‘s Global Portfolio